健康与疾病状态下血清免疫球蛋白的促甲状腺激素替代活性

Thyrotrophin displacement activity of serum immunoglobulins in health and disease.

作者信息

Croxson M S, Lim T M, Graham F M, Ibbertson H K

出版信息

Aust N Z J Med. 1980 Apr;10(2):151-6. doi: 10.1111/j.1445-5994.1980.tb03703.x.

DOI:10.1111/j.1445-5994.1980.tb03703.x

Abstract

A radioreceptor assay for TSH displacement activity (TDA) was employed as an index of thyroid stimulating immunoglobulins (TSlg) in serum from patients with autoimmune thyroid disease. TDA was less than or equal to 20 in normal subjects (37/37), patients without thyroid disease (36/38), non-toxic goitre (18/19) and toxic nodular goitre (16/17) and was significantly lower in Nepalese subjects with severe endemic goitre. TDA was greater than 20 in 84% of patients with untreated hyperthyroid Graves' disease (70/83), in Hashimoto's thyroiditis (3/17) and following subtotal thyroidectomy (8/14) or 131I therapy (7/11), but was less than or equal to 20 in euthyroid patients treated with carbimazole (58/59) and during spontaneous remission (18/19). Serial TDA measurements during antithyroid drug therapy suggested that carbimazole has a direct effect in reducing TSlg concentration but that TDA is not a useful prognostic indicator of short term relapse or remission.

摘要

采用促甲状腺激素替代活性（TDA）放射受体分析法作为自身免疫性甲状腺疾病患者血清中甲状腺刺激免疫球蛋白（TSlg）的指标。在正常受试者（37/37）、无甲状腺疾病患者（36/38）、非毒性甲状腺肿（18/19）和毒性结节性甲状腺肿（16/17）中，TDA小于或等于20，而在患有严重地方性甲状腺肿的尼泊尔受试者中TDA显著更低。在84%未经治疗的甲状腺功能亢进Graves病患者（70/83）、桥本甲状腺炎患者（3/17）以及甲状腺次全切除术后（8/14）或131I治疗后（7/11），TDA大于20，但在用卡比马唑治疗的甲状腺功能正常患者（58/59）以及自发缓解期间（18/19），TDA小于或等于20。在抗甲状腺药物治疗期间进行的连续TDA测量表明，卡比马唑对降低TSlg浓度有直接作用，但TDA并非短期复发或缓解的有用预后指标。